Clinical trial
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment…
NCT00101907 · Amgen, Industry · Terminated
Key facts
| NCT number | NCT00101907 |
|---|---|
| Title | Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer |
| Official title | An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer, Pancreatic Cancer, Esophageal Cancer |
| Intervention type | Biological, Drug |
| Interventions | AMG 706, Panitumumab, Gemcitabine, Cisplatin |
| Enrollment | 41 |
| Start date | Dec 1, 2004 |
| Primary completion | Jun 1, 2007 |
| Completion | Apr 1, 2008 |
| First posted | Jan 19, 2005 |
| Last update posted | Mar 20, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: